Holen Sie sich die Stockscreener-App
3.64
4.21%
-0.16
Schlusskurs vom Vortag:
$3.80
Offen:
$3.81
24-Stunden-Volumen:
689.16K
Relative Volume:
0.77
Marktkapitalisierung:
$318.27M
Einnahmen:
$32.77M
Nettoeinkommen (Verlust:
$-101.98M
KGV:
-0.3788
EPS:
-9.6101
Netto-Cashflow:
$-112.43M
1W Leistung:
-0.27%
1M Leistung:
-4.21%
6M Leistung:
+17.42%
1J Leistung:
-65.56%
1-Tages-Spanne:
$3.64
$3.86
1-Wochen-Bereich:
$3.57
$3.90
52-Wochen-Spanne:
$1.35
$26.83
X 4 Pharmaceuticals Inc Stock (XFOR) Company Profile
Firmenname
X 4 Pharmaceuticals Inc
Sektor
Branche
Telefon
857-529-8300
Adresse
61 NORTH BEACON STREET, BOSTON, MA
Vergleichen Sie XFOR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
XFOR
X 4 Pharmaceuticals Inc
|
3.64 | 332.26M | 32.77M | -101.98M | -112.43M | -9.6101 |
|
VRTX
Vertex Pharmaceuticals Inc
|
432.17 | 109.05B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
784.61 | 82.75B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
445.12 | 56.78B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
917.63 | 56.52B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.51 | 44.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
X 4 Pharmaceuticals Inc Stock (XFOR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-12-12 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2023-08-30 | Fortgesetzt | B. Riley Securities | Buy |
| 2022-12-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-12-12 | Eingeleitet | Piper Sandler | Overweight |
| 2019-12-23 | Eingeleitet | Oppenheimer | Outperform |
| 2019-12-18 | Eingeleitet | ROTH Capital | Buy |
| 2019-12-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-12-05 | Eingeleitet | B. Riley FBR | Buy |
| 2019-06-07 | Eingeleitet | Stifel | Buy |
| 2019-06-05 | Eingeleitet | Cowen | Outperform |
Alle ansehen
X 4 Pharmaceuticals Inc Aktie (XFOR) Neueste Nachrichten
Investors Don't See Light At End Of Universe Pharmaceuticals INC's (NASDAQ:UPC) Tunnel And Push Stock Down 31% - simplywall.st
Layoff Tracker: Novartis Cuts 550 Employees as Swiss Manufacturing Priorities Shift - BioSpace
Looking at the Narrative for X4 Pharmaceuticals After Leadership Changes and New Financing - Yahoo Finance
Head-To-Head Contrast: Werewolf Therapeutics (NASDAQ:HOWL) versus X4 Pharmaceuticals (NASDAQ:XFOR) - Defense World
X4 Pharmaceuticals (NASDAQ:XFOR) Upgraded to Hold at Wall Street Zen - Defense World
Is X4 Pharmaceuticals Inc. stock positioned for digital transformation2025 Price Action Summary & Comprehensive Market Scan Insights - newser.com
Why X4 Pharmaceuticals Inc. (48Q0) stock remains top ratedWeekly Trend Report & AI Enhanced Trading Alerts - newser.com
Will X4 Pharmaceuticals Inc. stock remain a Wall Street favorite2025 Short Interest & Growth Oriented Trading Recommendations - newser.com
X4 Pharmaceuticals Inc (XFOR) Performance and Fundamentals Dashboard tells a completely different story - Setenews
How to build a dashboard for X4 Pharmaceuticals Inc. stockWeekly Trade Analysis & Growth Oriented Trading Recommendations - newser.com
What moving averages say about X4 Pharmaceuticals Inc.2025 Year in Review & Momentum Based Trading Ideas - newser.com
Why X4 Pharmaceuticals Inc. stock could benefit from AI revolutionPortfolio Return Summary & Fast Gaining Stock Strategy Reports - newser.com
How strong is X4 Pharmaceuticals Inc. stock revenue growthJuly 2025 Decliners & Reliable Volume Spike Trade Alerts - newser.com
Is X4 Pharmaceuticals Inc. stock a buy in volatile marketsDollar Strength & High Yield Equity Trading Tips - newser.com
Will X4 Pharmaceuticals Inc. stock benefit from AI adoptionRisk Management & Technical Pattern Based Buy Signals - newser.com
Will X4 Pharmaceuticals Inc. stock benefit from commodity pricesChart Signals & Community Trade Idea Sharing Platform - newser.com
Fierce Biotech Layoff Tracker 2025: Kite cuts roles; Ventus undertakes 2nd layoff round this year - Fierce Biotech
Using economic indicators to assess X4 Pharmaceuticals Inc. potential2025 Price Targets & Advanced Swing Trade Entry Alerts - newser.com
Is X4 Pharmaceuticals Inc. (48Q0) stock a fit for income portfoliosFed Meeting & Comprehensive Market Scan Reports - newser.com
What analysts say about X4 Pharmaceuticals Inc 48Q0 stockPrice Action Trading & Backtest Your Strategy Before You Risk Money - earlytimes.in
Take off with X4 Pharmaceuticals Inc (XFOR): Get ready for trading - setenews.com
Goldman says healthcare is ripe for stock picking; here's some they like (XLV:NYSEARCA) - Seeking Alpha
What recovery options are there for X4 Pharmaceuticals Inc.Trade Exit Report & Low Drawdown Momentum Trade Ideas - newser.com
How dovish Fed policy supports X4 Pharmaceuticals Inc. (48Q0) stock2025 Market Outlook & Free Risk Controlled Daily Trade Plans - newser.com
Finanzdaten der X 4 Pharmaceuticals Inc-Aktie (XFOR)
Umsatz
Nettogewinn
Free Cashflow
ENV
X 4 Pharmaceuticals Inc-Aktie (XFOR) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Baldry Mark | Chief Commercial Officer |
May 16 '25 |
Buy |
2.48 |
1,032 |
2,561 |
25,337 |
| Ragan Paula | President and CEO |
Jan 24 '25 |
Sale |
0.45 |
76,473 |
34,719 |
1,087,386 |
| Mostafa Adam S. | Chief Financial Officer |
Jan 24 '25 |
Sale |
0.45 |
74,773 |
33,947 |
0 |
| Baldry Mark | Chief Commercial Officer |
Jan 24 '25 |
Sale |
0.45 |
29,159 |
13,241 |
94,123 |
| DiBiase Mary | Chief Operating Officer |
Jan 24 '25 |
Sale |
0.45 |
22,258 |
10,094 |
490,980 |
| Arbet-Engels Christophe | Chief Medical Officer |
Jan 24 '25 |
Sale |
0.45 |
11,624 |
5,284 |
14,207 |
0.76%
2.16%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):